| Advances Come in War on Cancer Researchers reported notable advances in the war on cancer over the weekend, including treatments for lung, ovarian and skin cancers, but they cautioned that the disease continues to throw up daunting obstacles. online.wsj.com |
Medicare to Weigh Coverage for Dendreon Drug The U.S. government said it would analyze whether covering the costs of Provenge, Dendreon's expensive immunotherapy treatment for prostate cancer, is "reasonable and necessary." online.wsj.com |
What Can Play Tricks on Your Memory Jeremy Singer-Vine summarizes new medical findings on false memory; muscle growth; walking speed and cognitive impairment; tai chi and fibromyalgia; autism; back pain. online.wsj.com |
Arena: This One-Trick Pony Is Safe to Short Arena (ARNA) is a safe short on any pop in the future, regardless of the panel vote result. FDA will not approve lorcaserin, period. The only thing holding ARNA from dropping directly to the abyss today is due to short- (smart money, over 40% recently) covering to lock in profit. Marginal efficacy, heart valve damage, rat tumor and memory loss.... It is near mission impossible for lorcaserin to receive FDA approval. If you may recall, early this year, FDA rejected Xenoport (XNPT) restless leg syndrom (RLS) drug, citing RLS is not a disease serious enough to justify the pre-clinical rat tumor discovery. Here, something familiar, lorcaserin greatly increases the cancer risk in rat pre-clinical study. Is obesity a life-threatening disease? Apparently no.Complete Story » seekingalpha.com |
New OTC Frequent Heartburn Treatment Hits Stores - Video ZEGERID OTC™ Hits Store Shelves; Offers Only Patented Dual-Ingredient Option for 24 Hour Frequent Heartburn Relief without a Prescription feedproxy.google.com |